UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 14, 2023 (
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation)
(Commission File Number) |
(I.R.S. Employer Identification No.) | |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number,
including area code: (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.03. | Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. |
On June 9, 2023, the Board of Directors (the “Board”) of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), based upon the recommendation of the Corporate Governance and Compliance Committee of the Board, approved an amendment (the “Amendment”) to Regeneron’s Amended and Restated By-Laws required in connection with the implementation of the previously adopted Board leadership succession plan, as disclosed in the Company’s Current Report on Form 8-K filed April 17, 2023 and the Company’s definitive proxy statement on Schedule 14A (under “Board Governance—Board Leadership Structure—Expected Future Board Leadership Structure”) filed April 21, 2023 (the “Proxy Statement”). The Amendment provides that the Board from time to time may elect two persons to serve as Co-Chairs of the Board and that, if there are Co-Chairs, either Co-Chair may exercise the full powers and authorities of the office.
The foregoing summary of the Amendment is qualified in its entirety by the full text of the Amendment, which is attached as Exhibit 3.2 hereto and is incorporated herein by reference.
Item 5.07. | Submission of Matters to a Vote of Security Holders. |
At the 2023 Annual Meeting of Shareholders of the Company held on June 9, 2023, Regeneron’s shareholders voted on the matters set forth below.
Proposal 1 – Election of Directors
The following nominees for Class II directors were elected to serve until the 2026 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes:
Nominee | For | Against | Abstain | Broker Non-Votes | ||||||||||||
Joseph L. Goldstein, M.D. | 78,930,855 | 33,390,357 | 196,082 | 4,209,777 | ||||||||||||
Christine A. Poon | 84,515,116 | 27,751,062 | 251,116 | 4,209,777 | ||||||||||||
Craig B. Thompson, M.D. | 111,784,253 | 644,879 | 88,162 | 4,209,777 | ||||||||||||
Huda Y. Zoghbi, M.D. | 108,341,947 | 4,126,763 | 48,584 | 4,209,777 |
Proposal 2 – Ratification of Appointment of Independent Registered Public Accounting Firm
The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, was approved based upon the following votes:
For: | 112,392,480 | |||
Against: | 4,290,618 | |||
Abstain: | 43,973 |
Proposal 3 – Advisory Vote on Executive Compensation
The resolution to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement was approved based on the following votes:
For: | 97,786,842 | |||
Against: | 14,490,406 | |||
Abstain: | 240,046 | |||
Broker Non-Votes: | 4,209,777 |
Proposal 4 – Advisory Vote on Frequency of Future Advisory Votes on Executive Compensation
One year was selected by a majority of the votes cast on the advisory proposal on the frequency of future advisory votes on executive compensation based upon the following votes:
One Year: | 111,204,155 | |||
Two Years: | 56,571 | |||
Three Years: | 1,192,972 | |||
Abstain: | 63,596 | |||
Broker Non-Votes: | 4,209,777 |
Proposal 5 – Non-binding Shareholder Proposal Requesting Report on a Process by which Access to Medicine is Considered in Matters Related to Protecting Intellectual Property
The non-binding shareholder proposal requesting report on a process by which access to medicine is considered in matters related to protecting intellectual property was not approved based upon the following votes:
For: | 10,554,422 | |||
Against: | 101,359,081 | |||
Abstain: | 603,791 | |||
Broker Non-Votes: | 4,209,777 |
Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
Exhibit No. | Description | |
3.2 | Amendment to the Amended and Restated By-Laws effective June 9, 2023. | |
104 | Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
REGENERON PHARMACEUTICALS, INC. | |
/s/ Joseph J. LaRosa | |
Joseph J. LaRosa | |
Executive Vice President, General Counsel and Secretary |
Date: June 14, 2023
Exhibit 3.2
AMENDMENT TO THE BY-LAWS
OF REGENERON PHARMACEUTICALS, INC.
This Amendment (this “Amendment”) to the Amended and Restated By-Laws of Regeneron Pharmaceuticals, Inc., as amended through December 16, 2016 and currently in effect (the “By-Laws”), hereby amends the By-Laws as follows:
1. | Section 7 of Article II of the By-Laws is hereby amended and restated in its entirety as follows: |
Section 7. Chairman of the Board. The Board of Directors from time to time may elect a Chairman of the Board. The Chairman of the Board, if one is elected, shall preside at all meetings of the Board of Directors and of the shareholders, and he shall have and perform such other duties as from time to time may be assigned to him by the Board of Directors. The Board of Directors from time to time may also elect two persons to serve as Co-Chairs of the Board (each, a “Co-Chair”). Any reference to the Chairman in these By-Laws shall be deemed to mean, if there are Co-Chairs, either Co-Chair, each of whom may exercise the full powers and authorities of the office.
2. | This Amendment is effective as of June 9, 2023. |
3. | As amended by this Amendment, the By-Laws shall remain in full force and effect. |
REGENERON PHARMACEUTICALS, INC. | |||
By: | /s/ Joseph J. LaRosa | ||
Name: | Joseph J. LaRosa | ||
Title: | Executive Vice President, General Counsel and Secretary |